| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
|
| | GS-9822 Basic information |
| Product Name: | GS-9822 | | Synonyms: | GS-9822;GS-9822;GS 9822;GS9822;6-Benzothiazoleacetic acid, 7-(4-chlorophenyl)-α-(1,1-dimethylethoxy)-5-methyl-2-[1-methyl-3-[1-(3-oxetanyl)-4-piperidinyl]-1H-indazol-5-yl]-, (αS)- | | CAS: | 2219362-41-9 | | MF: | C36H39ClN4O4S | | MW: | 659.24 | | EINECS: | | | Product Categories: | | | Mol File: | 2219362-41-9.mol |  |
| | GS-9822 Chemical Properties |
| Boiling point | 816.5±75.0 °C(Predicted) | | density | 1.38±0.1 g/cm3(Predicted) | | pka | 2.58±0.30(Predicted) |
| | GS-9822 Usage And Synthesis |
| Description | GS-9822 is a novel LEDGIN, an inhibitor that targets the binding pocket of LEDGF/p75 which is a cellular cofactor that substantially contributes to HIV integration site selection, displaying a block-and-lock phenotype in cell culture. | | Uses | GS-9822 is a potent antivira agent with nanomolar activity against wild-type HIV-1 viruses. GS-9822 potently inhibits the LEDGF/p75-integrase interaction with an IC50 of 0.07 μM. GS-9822 has high in vitro metabolic stability and favorable oral pharmacokinetic profiles with low systemic clearance in rats, dogs, and monkeys[1]. | | References | [1] Bruggemans A, et al. GS-9822, a preclinical LEDGIN candidate, displays a block-and-lock phenotype in cell culture. Antimicrob Agents Chemother. 2023 May 1;65(5):e02328-20. DOI:10.1128/AAC.02328-20 |
| | GS-9822 Preparation Products And Raw materials |
|